Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017524 · ClinicalTrials.gov registry record · Phase 1
AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00017524 is a Phase 1 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 22 participants.
The verdict
NCT00017524, a Phase 1 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of AG2037 in treating patients who have advanced, metastatic, or recurrent solid tumors.
Interventions
- DRUG pelitrexol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2001-03 |
| Est. Completion | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017524
The ClinicalTrials.gov registry entry for NCT00017524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pelitrexol is the first listed.
NCT00017524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017524 about?
NCT00017524 is a clinical study titled "AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of AG2037 in treating patients who have advanced, metastatic, or recurrent solid tumors.
What is the current status of trial NCT00017524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2001-03. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00017524?
The interventions under investigation include: pelitrexol (DRUG).
Who is sponsoring clinical trial NCT00017524?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.